Compare Stocks: IRWD, ABBV, NRIX, and BEAM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$252.19 +0.5%	$254.66	$190.75 ▼ $267.47	$445.19B	0.29	6.63 million shs	1.09 million shs
BEAM Beam Therapeutics	$24.26 -3.6%	$28.93	$19.57 ▼ $38.26	$2.51B	2.22	2.07 million shs	922,746 shs
IRWD Ironwood Pharmaceuticals	$3.96 -2.8%	$4.18	$1.15 ▼ $5.78	$653.52M	0.2	3.07 million shs	468,006 shs
NRIX Nurix Therapeutics	$25.59 -2.6%	$25.04	$8.19 ▼ $28.23	$2.65B	1.8	1.45 million shs	362,596 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+0.92%	-4.00%	+1.28%	+11.55%	+19.28%
BEAM Beam Therapeutics	-6.19%	-14.07%	-7.73%	-14.42%	+23.62%
IRWD Ironwood Pharmaceuticals	-2.40%	-7.71%	+0.49%	+12.12%	+266.67%
NRIX Nurix Therapeutics	+0.50%	+1.70%	+1.47%	+54.65%	+185.43%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$252.19 +0.5%	$254.66	$190.75 ▼ $267.47	$445.19B	0.29	6.63 million shs	1.09 million shs
BEAM Beam Therapeutics	$24.26 -3.6%	$28.93	$19.57 ▼ $38.26	$2.51B	2.22	2.07 million shs	922,746 shs
IRWD Ironwood Pharmaceuticals	$3.96 -2.8%	$4.18	$1.15 ▼ $5.78	$653.52M	0.2	3.07 million shs	468,006 shs
NRIX Nurix Therapeutics	$25.59 -2.6%	$25.04	$8.19 ▼ $28.23	$2.65B	1.8	1.45 million shs	362,596 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+0.92%	-4.00%	+1.28%	+11.55%	+19.28%
BEAM Beam Therapeutics	-6.19%	-14.07%	-7.73%	-14.42%	+23.62%
IRWD Ironwood Pharmaceuticals	-2.40%	-7.71%	+0.49%	+12.12%	+266.67%
NRIX Nurix Therapeutics	+0.50%	+1.70%	+1.47%	+54.65%	+185.43%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.88	Moderate Buy	$276.64	9.69% Upside
BEAM Beam Therapeutics	2.69	Moderate Buy	$49.00	102.00% Upside
IRWD Ironwood Pharmaceuticals	2.57	Moderate Buy	$6.23	57.61% Upside
NRIX Nurix Therapeutics	2.80	Moderate Buy	$34.21	33.70% Upside

Current Analyst Ratings Breakdown

Latest IRWD, ABBV, NRIX, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	ABBV AbbVie	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$300.00 ➝ $315.00
9/9/2026	BEAM Beam Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$65.00
9/8/2026	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/4/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
8/25/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$80.00
8/21/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C+)
8/20/2026	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$298.00 ➝ $303.00
8/17/2026	ABBV AbbVie	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$295.00 ➝ $300.00
8/13/2026	ABBV AbbVie	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$300.00
8/11/2026	ABBV AbbVie	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$218.00 ➝ $247.00
8/10/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$61.16B	7.29	$15.36 per share	16.42	($1.83) per share	-137.81
BEAM Beam Therapeutics	$139.74M	17.93	N/A	N/A	$12.20 per share	1.99
IRWD Ironwood Pharmaceuticals	$389.32M	1.68	$0.24 per share	16.20	($1.61) per share	-2.46
NRIX Nurix Therapeutics	$83.98M	31.62	N/A	N/A	$5.29 per share	4.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.23B	$3.54	71.18	15.62	1.13	9.80%	-422.07%	14.34%	10/30/2026 (Estimated)
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	11/3/2026 (Estimated)
IRWD Ironwood Pharmaceuticals	$24.02M	$0.77	5.14	N/A	N/A	33.36%	-58.38%	34.93%	11/9/2026 (Estimated)
NRIX Nurix Therapeutics	-$264.46M	-$3.45	N/A	N/A	N/A	-928.44%	-76.09%	-57.31%	10/8/2026 (Estimated)

Latest IRWD, ABBV, NRIX, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/8/2026	Q3 2026	NRIX Nurix Therapeutics	-$0.6009	N/A	N/A	N/A	$24.35 million	N/A
8/6/2026	Q2 2026	IRWD Ironwood Pharmaceuticals	$0.32	$0.31	-$0.01	$0.31	$114.84 million	$113.04 million
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million
7/31/2026	Q2 2026	ABBV AbbVie	$3.61	$3.65	+$0.04	$2.03	$16.80 billion	$16.99 billion
7/9/2026	Q2 2026	NRIX Nurix Therapeutics	-$0.73	-$0.81	-$0.08	-$0.81	$15.29 million	$9.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.92	2.74%	+6.80%	195.48%	53 Years
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest IRWD, ABBV, NRIX, and BEAM Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/18/2026	ABBV AbbVie	quarterly	$1.73	2.83%	7/15/2026	7/15/2026	8/14/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	N/A	0.81	0.69
BEAM Beam Therapeutics	0.09	14.57	14.57
IRWD Ironwood Pharmaceuticals	N/A	6.06	6.06
NRIX Nurix Therapeutics	N/A	6.34	6.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
BEAM Beam Therapeutics	99.68%
IRWD Ironwood Pharmaceuticals	N/A
NRIX Nurix Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.06%
BEAM Beam Therapeutics	3.80%
IRWD Ironwood Pharmaceuticals	9.30%
NRIX Nurix Therapeutics	6.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	57,000	1.77 billion	1.77 billion	Optionable
BEAM Beam Therapeutics	510	103.29 million	99.36 million	Optionable
IRWD Ironwood Pharmaceuticals	220	165.24 million	149.87 million	Optionable
NRIX Nurix Therapeutics	300	103.78 million	96.83 million	Optionable

IRWD, ABBV, NRIX, and BEAM Headlines

Recent News About These Companies

Here's Why You Should Add NRIX Stock to Your Portfolio Now

2 hours ago | zacks.com

Nurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

4 hours ago | seekingalpha.com

Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why

September 9 at 1:00 PM | zacks.com

Legal & General Group Plc Buys Shares of 72,026 Nurix Therapeutics, Inc. $NRIX

September 7 at 4:55 AM | marketbeat.com

Nurix Therapeutics (NASDAQ:NRIX) Downgraded by Wall Street Zen to "Sell"

September 5, 2026 | americanbankingnews.com

Wall Street Zen Downgrades Nurix Therapeutics (NASDAQ:NRIX) to Sell

September 5, 2026 | marketbeat.com

Bank of New York Mellon Corp Purchases New Shares in Nurix Therapeutics, Inc. $NRIX

September 4, 2026 | marketbeat.com

Braidwell LP Cuts Position in Nurix Therapeutics, Inc. $NRIX

September 3, 2026 | marketbeat.com

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Rating of "Moderate Buy" by Analysts

September 3, 2026 | americanbankingnews.com

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Analysts

September 3, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and Nurix Therapeutics (NRIX)

September 2, 2026 | theglobeandmail.com

Gwenn Hansen Sells 1,452 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

September 2, 2026 | insidertrades.com

Man Group plc Makes New $2.08 Million Investment in Nurix Therapeutics, Inc. $NRIX

September 2, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Acquires New Holdings in Nurix Therapeutics, Inc. $NRIX

September 2, 2026 | marketbeat.com

Alyeska Investment Group L.P. Takes $3.35 Million Position in Nurix Therapeutics, Inc. $NRIX

September 2, 2026 | marketbeat.com

Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 1,452 Shares of Stock

September 1, 2026 | marketbeat.com

Nurix Therapeutics to Participate in Upcoming September Investor Conferences

September 1, 2026 | globenewswire.com

Nurix Advances NX-5948 Combo Trial in B-Cell Cancers, Setting Up Key Catalyst for NRIX

August 28, 2026 | tipranks.com

BlackRock Inc. Buys New Position in Nurix Therapeutics, Inc. $NRIX

August 28, 2026 | marketbeat.com

Trails Edge Capital Partners LP Invests $38.17 Billion in Nurix Therapeutics, Inc. $NRIX

August 26, 2026 | marketbeat.com

Elmind Capital LP Makes New Investment in Nurix Therapeutics, Inc. $NRIX

August 26, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IRWD, ABBV, NRIX, and BEAM Company Descriptions

AbbVie NYSE:ABBV

$252.19 +1.28 (+0.51%)

As of 12:56 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Beam Therapeutics NASDAQ:BEAM

$24.26 -0.91 (-3.62%)

As of 12:55 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Ironwood Pharmaceuticals NASDAQ:IRWD

$3.96 -0.12 (-2.83%)

As of 12:55 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Nurix Therapeutics NASDAQ:NRIX

$25.59 -0.67 (-2.55%)

As of 12:56 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IRWD, ABBV, NRIX, and BEAM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IRWD, ABBV, NRIX, and BEAM Earnings

Compare Dividends

Latest IRWD, ABBV, NRIX, and BEAM Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IRWD, ABBV, NRIX, and BEAM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IRWD, ABBV, NRIX, and BEAM Company Descriptions

AbbVie NYSE:ABBV

Beam Therapeutics NASDAQ:BEAM

Ironwood Pharmaceuticals NASDAQ:IRWD

Nurix Therapeutics NASDAQ:NRIX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools